U.S. markets open in 2 hours 34 minutes
  • S&P Futures

    3,449.00
    +26.25 (+0.77%)
     
  • Dow Futures

    28,288.00
    +188.00 (+0.67%)
     
  • Nasdaq Futures

    11,745.50
    +95.25 (+0.82%)
     
  • Russell 2000 Futures

    1,627.30
    +16.00 (+0.99%)
     
  • Crude Oil

    40.96
    +0.13 (+0.32%)
     
  • Gold

    1,909.10
    -2.60 (-0.14%)
     
  • Silver

    24.75
    +0.05 (+0.21%)
     
  • EUR/USD

    1.1813
    +0.0040 (+0.34%)
     
  • 10-Yr Bond

    0.7610
    0.0000 (0.00%)
     
  • Vix

    28.32
    +0.91 (+3.32%)
     
  • GBP/USD

    1.2949
    +0.0009 (+0.07%)
     
  • USD/JPY

    105.5970
    +0.1670 (+0.16%)
     
  • BTC-USD

    11,835.45
    +778.44 (+7.04%)
     
  • CMC Crypto 200

    239.29
    +5.62 (+2.40%)
     
  • FTSE 100

    5,901.52
    +16.87 (+0.29%)
     
  • Nikkei 225

    23,567.04
    -104.09 (-0.44%)
     

MEI Pharma's cancer drug misses main goals in mid-stage study

March 23 (Reuters) - MEI Pharma says its cancer drug failed to meet the main goal in a mid-stage study.

The drug, pracinostat, in combination with chemotherapy drug azacitidine showed no difference in complete remission in previously untreated patients with myelodysplastic syndrome (MDS) - a type of blood cancer - against azacitidine alone.

Complete remission implies the disappearance of all signs of cancer in response to treatment. It does not always constitute a cure.

(Reporting by Rosmi Shaji in Bengaluru; Editing by Saumyadeb Chakrabarty)